In a systematic literature review, researchers found that rheumatoid arthritis patients taking etanercept were less likely to discontinue their treatment than patients using any of five other tumor necrosis factor inhibitors…
Antibiotic Use Linked to Higher Risk for RA
New research finds patients previously treated with antibiotics, antifungals and antivirals may be more likely to develop rheumatoid arthritis than patients who have not received these treatments…
Physical Activity Reduces Risk of Rheumatoid Arthritis
A recent study has taken a more detailed look at the relationship between physical activity and the risk of developing rheumatoid arthritis (RA). Researchers found the more patients exercised weekly the lower their overall risk, specifically brisk and very brisk walking paces, along with longer cumulative average walking hours weekly were associated with a reduced risk for RA…
New Options for Treatment-Resistant RA
Two JAK inhibitors, one recently approved by the FDA, have shown improvements in patients with active RA for whom other therapies have proved ineffective…
Abx464 Enters Phase 2 Clinical Trials for RA in Europe
In Europe, researchers are evaluating the safety, tolerability and efficacy of ABX464 in rheumatoid arthritis patients…
Catch Your Breath: Insights into ILD in RA Patients
Detecting interstitial lung disease in RA patients can be challenging. But evaluating risk factors and the use of imaging can help clinicians identify and manage this condition in patients…
FDA Approves Upadacitinib for RA
Results from multiple phase 3 clinical trails have led to the FDA approval of upadacitinib to treat patients with moderate to severe active RA…
Long-Term Physical Activity Lowers the Risk of RA among Women
A new study adds to the evidence that metabolic factors play an important role in the pathogenesis of rheumatoid arthritis (RA). In this large, prospective cohort study, Liu et al. found that increased physical activity among women was associated with a reduced risk of RA…
Filgotinib Promising for RA
Research shows filgotinib may be safe and effective for treating rheumatoid arthritis. The drug’s manufacturer is expected to be submit a new drug application for filgotinib to the FDA in 2019…
FDA Approves AbbVie’s New Rheumatoid Arthritis Drug
(Reuters)—The U.S. Food and Drug Administration (FDA) on Friday approved AbbVie Inc.’s new treatment for rheumatoid arthritis (RA), a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira (adalimumab) faces competition. The drug, Rinvoq (upadacitinib), is a JAK inhibitor. It is set to compete with Pfizer Inc.’s Xeljanz (tofacitinib)…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 30
- Next Page »